Avidity Partners Management LP Cuts Stake in Pfizer Inc. $PFE

Avidity Partners Management LP trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 44.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 203,600 shares of the biopharmaceutical company’s stock after selling 162,800 shares during the quarter. Pfizer accounts for about 1.5% of Avidity Partners Management LP’s investment portfolio, making the stock its 15th biggest position. Avidity Partners Management LP’s holdings in Pfizer were worth $5,070,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. State Street Corp increased its position in shares of Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after acquiring an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after acquiring an additional 1,184,728 shares during the last quarter. Morgan Stanley increased its position in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth about $1,830,986,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.1%

Shares of Pfizer stock opened at $26.19 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $26.43 and a 200 day moving average price of $26.32. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The firm has a market cap of $149.26 billion, a P/E ratio of 19.99 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the firm posted $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Barclays initiated coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Finally, HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.